The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A | Alive

Total Raised


Last Raised

$60M | 2 mos ago

About Ancora Biotech

Ancora Biotech is a developer of biotherapeutics for B cell cancers, metabolic diseases, and chronic Hepatitis B infections. It is a service provider supporting clinical development of assets for TeneoTwo, TeneoFour, and TeneoTen. The company oversees the manufacturing and clinical development of these assets, including TeneoTwo’s clinical stage TNB-486 (anti-CD19xCD3); TeneoFour’s preclinical TNB-738, an anti-CD38 enzyme inhibitor and anti-inflammatory poised to enter Phase I clinical studies in Q1 2022; and TeneoTen’s development of preclinical anti-HBVxCD3 for the treatment of chronic hepatitis B. Ancora Biotech was founded in 2021 and is based in Newark, California.

Ancora Biotech Headquarters Location

Newark, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Ancora Biotech News

Big Teneo: Astrazeneca to buy Teneotwo in a deal worth up to $1.27B

Jul 5, 2022

July 5, 2022 To build on its hematology pipeline in treating blood cancers, Astrazeneca plc is acquiring Teneotwo Inc. in a deal that could reach $1.27 billion. Teneotwo is part of Ancora Biotech LLC, which has some other affiliate Tens in the stable, including Teneofour Inc. That company is developing TNB-738, an anti-CD38 enzyme inhibitor. Teneoten Inc. is developing an anti-HBV/CD3 therapy. Both are available for partnering or sale, Ben Buelow, Ancora co-founder, told BioWorld. He co-founded the company with this father, Roland.

  • When was Ancora Biotech founded?

    Ancora Biotech was founded in 2021.

  • Where is Ancora Biotech's headquarters?

    Ancora Biotech's headquarters is located at Newark.

  • What is Ancora Biotech's latest funding round?

    Ancora Biotech's latest funding round is Series A.

  • How much did Ancora Biotech raise?

    Ancora Biotech raised a total of $60M.

  • Who are the investors of Ancora Biotech?

    Investors of Ancora Biotech include Lightspeed Venture Partners and SR One.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.